ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Products The company’s main product candidate is Gencaro (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator that it intends to evaluate in a new clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure and/or left ventricular dysfunction (HFREF). The company intends to test this hypothesis in a Phase 2B/3 clinical trial of Gencaro, known as GENETIC-AF. GENETIC-AF is planned as a multi-center, randomized, double-blind clinical trial designed to compare the safety and efficacy of Gencaro to an active comparator, the beta-blocker Toprol XL (metoprolol succinate). Strategy The company pursues the following strategies: advancing the development of Gencaro; raising additional funding or complete a strategic transaction; building a cardiovascular pipeline; and leveraging existing assets. Research and Development The company’s research and development expenses totaled $2.9 million, as of December 31, 2013.
arca biopharma inc (ABIO:NASDAQ CM)
11080 CirclePoint Road
Westminster, CO 80020
|No competitor information is available for ABIO.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact ARCA BIOPHARMA INC, please visit www.arcabiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.